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Abstract
Background: Regular off-treatment imaging is often used to assess for recurrence 
of disease after childhood cancer treatment. It is unclear if this increases survival, or 
what burden surveillance places on patients, families, or health-care services. This 
systematic review examines the impact of routine surveillance imaging after treat-
ment of pediatric extracranial solid tumors.
Methods: Collaborative patient and public involvement informed the design and in-
terpretation of this work. Thirteen electronic databases, conference proceedings, and 
trial registries were searched alongside reference list checking and forward citation 
searching from 1990 onwards. Studies were screened and data were extracted by two 
researchers. Risk of bias was assessed using a modified ROBINS-I tool. Relevant 
outcomes were overall survival, psychological distress indicators, number of imag-
ing tests, cost-effectiveness, and qualitative data regarding experiences of surveil-
lance programs. PROSPERO (CRD42018103764).
Results: Of 17 727 records identified, 55 studies of 10 207 patients were included. 
All studies used observational methods. Risk of bias for all except one study was 
moderate, serious, or critical. Data were too few to conduct meta-analysis; however, 
narrative synthesis was performed. Surveillance strategies varied, and poorly re-
ported, involving many scans and substantial radiation exposure (eg, neuroblastoma, 
median 133.5 mSv). For most diseases, surveillance imaging was not associated with 
increased overall survival, with the probable exception of Wilms tumor. No qualita-
tive or psychological distress data were identified.
Conclusions: At present, there is insufficient evidence to evaluate the effects of rou-
tine surveillance imaging on survival in most pediatric extracranial solid tumors. 
More high-quality data are required, preferably through randomized controlled trials 
with well-conducted qualitative elements.
K E Y W O R D S
adolescent, diagnostic imaging, neoplasms, pediatrics, population surveillance
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1 |  INTRODUCTION
Following completion of treatment for childhood malignancy, 
regular imaging studies are frequently used alongside clinical 
review to assess for recurrence of disease.1 It is anticipated 
that imaging may identify relapse before signs and symptoms 
develop, allowing earlier or less intensive treatment with an 
increased chance of survival.2
However, there has been some suggestion that this is not 
the case, as recurrence may still be detected clinically, and 
detection via imaging may not increase overall survival.1,3,4 
Surveillance imaging comes with costs, including a psycho-
logical burden on families, possible increased risk of second 
malignancy, incidental findings, and increased exposure to 
general anesthesia, along with financial and opportunity costs 
to health services.2,4
This systematic review seeks to establish if routine sur-
veillance imaging after treatment of pediatric extracranial 
solid tumors causes more harm than good, specifically exam-
ining the impact on overall survival, anxiety and other psy-
chological distress, number of scans received, radiation dose, 
other harms of surveillance, and cost-effectiveness.
2 |  METHODS
The review protocol was prospectively registered on 
PROSPERO (CRD42018103764) and published.5
2.1 | Patient and public involvement
A patient and public involvement (PPI) group steered the 
review from the outset, ranking important outcomes, under-
standing the context and implications of the results, including 
further research needs, and active involvement in the dissem-
ination of the research. A young person with experience of 
childhood cancer summarized the review to be accessible to 
high-school students (Supplemental File 1).
2.2 | Searches
Electronic searches were undertaken from 1990 onwards, 
reflecting the current era of survival in childhood cancer. 
Published and unpublished studies were sought and no lan-
guage or study design restrictions were applied, as such 
randomized controlled trials, quasi-randomized studies, pro-
spective, and retrospective cohort studies were all eligible 
to be included, as described in the protocol.5 The following 
databases were searched in July 2018: MEDLINE (Epub 
Ahead of Print, In-Process & Other Non-Indexed Citations, 
Ovid MEDLINE Daily, and Ovid MEDLINE), PubMed, 
EMBASE, PsycINFO, Cumulative Index to Nursing & Allied 
Health (CINAHL Plus), Science Citation Index, Conference 
Proceedings Citation Index—Science, Cochrane Database 
of Systematic Reviews (CDSR), Cochrane Central Register 
of Controlled Trials (CENTRAL), Health Technology 
Assessment (HTA) database, Database of Abstracts of Reviews 
of Effects (DARE), NHS Economic Evaluation Database 
(NHS EED), PROSPERO, and EconLit. (Supplemental File 
2). Searches of conference proceedings of the RCPCH (Royal 
College of Paediatrics and Child Health), SIOP (International 
Society of Paediatric Oncology), ASPHO (American Society 
of Paediatric Hematology/Oncology), ASCO (American 
Society of Clinical Oncology), and ASH (American Society 
of Hematology), along with ClinicalTrials.gov and the WHO 
International Clinical Trials Registry Platform portal were un-
dertaken. Reference lists of relevant systematic reviews and 
Box 1 Study inclusion and exclusion criteria
Inclusion criteria: 
- Population: Children or young people up to 25 
years who had completed treatment for a ma-
lignant extracranial solid tumour and had no 
evidence of active and ongoing disease at end of 
treatment (or results for this subgroup)
- Intervention: programme of surveillance imag-
ing aiming to detect relapse of previously treated 
childhood cancer
- Comparators: routine clinical review, another 
surveillance programme (using imaging or labo-
ratory measures) or none (some studies reported 
this comparison as detection of relapses by sur-
veillance compared to by symptoms)
Outcomes: 
a. Primary: Overall Survival (age at time of death or 
time from original diagnosis)
b. Secondary: psychological distress indicators, 
number of imaging tests, cost-effectiveness, quali-
tative data relating to experiences of surveillance 
imaging, other harms of imaging (as identified by 
the studies themselves)
Exclusion criteria 
- Case studies
- Studies from Low and Middle-Income Countries 
(LMIC) - Only studies performed in high-income 
countries were included, to reflect the treatment 
and surveillance strategies in these settings.
- Surveillance solely related to patients with cancer 
predisposition syndromes
- Surveillance looking predominantly for late ef-
fects of treatment
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included articles were reviewed and forward citation search-
ing of included articles was performed, using Web of Science.
2.3 | Screening and data extraction
For inclusion and exclusion criteria see Box 1. Two au-
thors independently screened the title and abstract of 
studies, dual-screening 10% of the records and single-
screening the remaining 90% as agreement was good 
(96.6%). Disagreements were resolved by consensus, or by 
recourse to a third author. Data extraction was performed 
by two authors. Study quality was assessed using a modi-
fied ROBINS-I tool, supplemented with potential sources 
of heterogeneity: patient demographic and clinical charac-
teristics, study era, and geography.6,7
2.4 | Analysis
Key study characteristics were summarized in narrative and 
tabular forms. Given the degree of clinical heterogeneity and 
absence of sufficient data, meta-analysis was not appropriate. 
Narrative synthesis was performed by tumor type, and focused 
on the key themes of: method of identification of relapse, bur-
den of surveillance programs, and effects on survival.
3 |  RESULTS
About 17 727 unique records were identified by the search, 
17 226 were excluded on title and abstract, and 449 excluded 
following full-text review (Figure 1). Review of conference 
proceedings and references searches identified three further 
studies. Review of trial registries identified no ongoing rel-
evant studies.
3.1 | Mapping summary
Fifty-five studies, with 10  423 participants, were included 
(Table  1). Most (48/55) studies were retrospective cohort 
studies. Twelve studies reported “mixed malignancies” 
where patients with more than one type of malignancy were 
included, including mixed lymphomas.1,8–18 These studies do 
not provide sufficient granularity to advise clinical decision-
making and as such are not discussed further in this paper, in-
formation relating to these are provided in Supplemental File 
3. Wilms tumor was the most frequently studied malignancy. 
Surveillance programs were poorly reported. Eight main 
imaging modalities were assessed (CT, gallium scan, ultra-
sound, X-ray, MRI, FDG-PT, bone scan, and MIBG), with 
most studies (32/55) assessing more than one modality and 
CT most commonly used (32/55 studies). In many studies, it 
F I G U R E  1  Flow diagram for study 
selection
17 152 references idenfied 
by database searches (a
er 
removal of duplicates)
17 226 excluded a
er review of tle 
and abstract
501 full text arcles 
retrieved
Excluded a
er review of full text:
262 excluded on age group
20 excluded on disease
11 excluded on seng
80 excluded on topic
9   excluded on outcomes
59 excluded on study design
8   excluded as duplicate data
55 included in the review
3 included from reference lists
144 from trial registries
431 from forward citaon searches
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T A B L E  1  Study characteristics
Study
Year of 
publication Disease Country
N 
participants
N participants 
experiencing 
relapse
Age 
(median1, 
mean
2)
Details of surveillance program
Mode Frequency
Maximum 
follow-up 
period
Bayar19 2000 NHL US 44 0 8.332 CT, Gallium scans 3-6 mo 6
Borst20 2013 NHL US 12 0 12.422 CT, Gallium scans, 
MRI, FDG-PET, 
Bone scan
Every 3 mo for 12-24 mo, 
decreasing with time
10
Eissa21 2014 NHL US 44 3 8.882 CT, Gallium scans, 
X-ray, FDG-PET
NR 10
Karantanis22 2010 NHL US 10 0 36.12 CT, FDG-PET NR NR
Friedmann23 2013 Hodgkin's lymphoma US 402 64 15.61 CT, Gallium scans, 
X-ray, FDG-PET
Every 3 mo for 1 y, 
decreasing with time
18.3
Levine24 2006 Hodgkin's lymphoma US 47 3 151 CT, FDG-PET NR 5
Meany25 2007 Hodgkin's lymphoma US 25 2 14.22 CT, FDG-PET Every 3 mo for 2 y 3.83
Voss26 2012 Hodgkin's lymphoma US 219 25 NR CT, Gallium scans NR NR
Wickmann27 2003 Hodgkin's lymphoma Germany 15 13 NR CT, MRI, FDG-PET Every 6 mo, decreasing 
with time
NR
Chang31 2015 Osteosarcoma South Korea 153 9 172 FDG-PET Every 3-6 mo for 2 y, 
decreasing with time
7.67
Korholz28 1998 Osteosarcoma Germany 78 28 141 CT, X-ray, Bone scan, 
Other
Every 3-6 mo for 1-2 y, 
decreasing with time
15.11
Korholz29 1996 Osteosarcoma Germany 78 28 141 CT, X-ray, Bone scan, Monthly or bimonthly for 
1-2 y, decreasing with 
time
NR
Massera32 1994 Osteosarcoma Italy 16 6 192 CT NR NR
Korholz30 2000 Osteosarcoma & 
Ewing's sarcoma
Germany 119 7 151 CT, X-ray, Bone scan, NR 14
Cash33 2013 Ewing's sarcoma US 71 21 NR NR NR NR
Heinemann34 2018 Ewing's sarcoma Germany 180 30 13.81 CT, X-ray, MRI, 
FDG-PET, Bone 
scan
Every 1.5 and 3 mo for 
1 y, decreasing with time
5
Heinemann35 2017 Ewing's sarcoma Germany 284 160 151 CT, X-ray, FDG-PET, 
Bone scan
Every 1.5 and 3 mo for 
1 y, decreasing with time
12
(Continues)
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Study
Year of 
publication Disease Country
N 
participants
N participants 
experiencing 
relapse
Age 
(median1, 
mean
2
)
Details of surveillance program
Mode Frequency
Maximum 
follow-up 
period
Brok36 2018 Wilms tumor Brazil, France, 
Germany, Netherlands, 
UK
4271 538 4.221 Ultrasound, X-ray Every 3 monthly for 
12-24 mo, decreasing 
with time
10
Carrico37 1997 Wilms tumor US 60 7 3.52 Ultrasound, X-ray Between 6 wks and 3 mo, 
variable on disease stage
5
Daw38 2002 Wilms tumor US 280 8 301 CT, Ultrasound NR NR
Kaste39 2013 Wilms tumor US 110 16 2.921 CT NR NR
Mullen40 2018 Wilms tumor US, Canada, Australia, 
New Zealand, 
Switzerland, and 
Netherlands
336 281 NR CT, Ultrasound, X-ray NR NR
Davini41 2018 Hepatoblastoma US 31 NR NR CT NR NR
Rojas42 2014 Hepatoblastoma US 26 5 2.332 CT, Ultrasound, MRI, 
FDG-PET
Every 3 mo for 1 y, then at 
discretion of oncologist
NR
Bruggers43 1998 Neuroblastoma US 32 22 3.752 NR NR NR
Federico44 2015 Neuroblastoma US 78 46 2.71 CT, MIBG NR NR
Kushner45 2009 Neuroblastoma US 154 154 NR CT, MIBG Every 2 to 4 months NR
Okuyama46 2002 Neuroblastoma Japan 40 5 1.21 MIBG Every 3-12 mo, variable 
with disease stage
NR
Owens47 2016 Neuroblastoma Canada 183 50 3.541 MRI, MIBG NR NR
Cogswell50 1994 Rhabdomyosarcoma Australia 40 10 5.831 Gallium scans, X-ray, 
Bone scan
Every 3 mo for 2 y, 
decreasing with time
NR
Lin3 2016 Rhabdomyosarcoma US 145 24 13.52 NR NR NR
Mallebranche52 2017 Rhabdomyosarcoma France 99 NR 51 Ultrasound, X-ray Every 2 mo for 2 y, 
decreasing with time
NR
Vaarwerk51 2018 Rhabdomyosarcoma UK 182 182 NR NR NR 17.7
Sirin48 2016 Retinoblastoma Germany 50 3 1.172 MRI NR 6
White49 1991 Retinoblastoma Australia, US 15 0 212 Bone scan Every 4 mo, decreasing 
with time
5
Lobeck53 2017 Appendiceal carcinoid 
tumors
US 30 0 13.52 CT, Ultrasound, MRI NR 5.33
T A B L E  1  (Continued)
(Continues)
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was unclear whether surveillance imaging was within a clini-
cal trial or part of routine care.
3.2 | Risk of bias
Risk of bias was variable, with most studies demonstrating 
moderate to serious risk of bias (Table 2). Particular issues 
relate to confounding and lead-time bias (where studies 
measure survival from time of detection of relapse, rather 
than from original diagnosis).
3.3 | Analysis
3.3.1 | Lymphomas
Non-Hodgkin’s lymphoma
Four studies examined surveillance imaging in 110 patients 
with non-Hodgkin’s lymphoma.19–22 Data from three of four 
studies indicated large numbers of scans, with 806 scan con-
ducted in 66 patients.20–22 Where reported, scanning was 
associated with notable radiation dose (median whole body 
radiation dose of 40.3-91.3 MSv).20,21
Three relapses occurred within one study population in 
a median time of 0.25 years. These were detected by symp-
toms.21 Surveillance imaging detected no relapse and pro-
duced 17 false positive images.19,20,22
Hodgkin’s lymphoma
Five studies assessed surveillance imaging in 799 patients 
with Hodgkin’s lymphoma.23–27 Surveillance programs com-
prised large numbers of images, where reported, 1293 in 291 
patients.24–26
Relapse was detected in 111 (13.8%) patients, 51 (45.9%) 
by surveillance imaging and 60 (45.1%) by clinical signs and 
symptoms. Thirty-four false positive images were reported in 
two studies.24,25
One study reported a median time to relapse of 1.7 years 
by scan compared to 0.61 years in those detected by clini-
cal signs and symptoms.26 For those relapses detected after 
12  months off-treatment, 5-year survival after relapse was 
100% for both groups.26 Another study reported 5-year sur-
vival after relapse in those detected by surveillance imaging 
64.6% ± 10.1% vs clinical signs and symptoms 73.8% ± 7.2% 
(P = .186).23
3.3.2 | Osteosarcoma
Five studies of three cohorts reported on 247 patients with os-
teosarcoma.28–32 Where reported, the number of scans during 
surveillance programs was large, 2394 for 231 patients.28,31S
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T A B L E  2  Risk of bias for studies
Study Year Confounding
Patient 
selection Protocol deviation Missing data
Knowledge of intervention 
and recording of outcome Effect estimate
Overall judgment 
of risk
Bayar19 2000 Moderate
Berrettini60 2015 Moderate
Borst20 2013 Moderate
Brok36 2018 Serious
Bruggers43 1998 Moderate
Carrico37 1997 Low
Cash33 2013 Moderate
Chang31 2015 Moderate
Cheuk56 2012 Moderate
Cogswell50 1994 Moderate
Davini41 2018 Moderate
Daw38 2002 Moderate
Eissa21 2014 Moderate
Federico44 2015 Moderate
Friedmann23 2013 Serious
Geldart54 2006 Serious
Halalsheh55 2018 Moderate
Heinemann34 2018 Moderate
Heinemann35 2017 Serious
Karantanis22 2010 Moderate
Kaste39 2013 Moderate
Korholz28 1998 Moderate
Korholz29 1996 Serious
Korholz30 2000 Serious
Kushner45 2009 Serious
Laddie58 2009 Moderate
Levine24 2006 Moderate
Lin3 2016 Moderate
Lobeck53 2017 Moderate
Mallebranche52 2017 Critical
Massera32 1994 Moderate
(Continues)
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Forty-three patients experienced relapse, with one study 
providing comparative data on the numbers of patients who 
experienced relapse detected by surveillance imaging vs 
symptoms, 7/28 vs 21/28, respectively.28 Survival data were 
largely lacking. Korholz et al reported a 5-year overall sur-
vival of 67%, without comparative data on the method of re-
lapse detection.28
3.3.3 | Ewing’s sarcoma
Four studies of three cohorts of 355 patients with Ewing’s 
sarcoma were reported.30,33–35 About 181 patients relapsed, 
87 (48.0%) of which were detected by surveillance imaging 
and 94 (52.0%) by clinical signs and symptoms.
One study reported a shorter median time to relapse, 
0.28 vs 1.22 years, and a lower 5-year survival, 0% vs 17%, 
in symptomatic patients compared to those detected by sur-
veillance imaging.33 Another study also reported a shorter 
nonsignificant median time to relapse, 1.6 vs 1.9  years 
(P  =  .07), between symptomatic and surveillance detec-
tion.34 Another study found that 5-year overall survival 
(OS) after relapse was higher in asymptomatic patients vs 
symptomatic patients, 37% vs 9%.35
3.3.4 | Wilms tumor
Six studies explored five cohorts of 5074 patients with 
Wilms tumor.17,36–40 These experienced 836 relapses; where 
method of relapse detection was reported, 501 were detected 
by surveillance imaging and 181 detected by symptoms. Not 
all patients had method of relapse detection reported.
Three of the cohorts contributed few data, with < 20 re-
lapses per study.37–39 From the two larger cohorts, 5-year 
OS after relapse was 56% and 67%.36,40 Overall survival for 
those detected by surveillance vs symptoms was 70% (95% 
CI, 63% to 77%) vs 59% (95% CI, 46% to 72%).40 One study 
reported a lower median duration of survival after relapse for 
patients detected by symptoms (22 months with symptoms, 
not reached for asymptomatic, hazard ratio 1.84 (95% CI 
1.24-2.74)).36
Other relevant outcomes included the number of scans to 
detect one subclinical relapse of 112 (95% CI 106-119) during 
the first 2 years after nephrectomy and 500 (95% CI 416-588) 
2-5 years after nephrectomy and a cost for follow-up studies 
of $347,968 per patient.36,37
3.3.5 | Hepatoblastoma
There were 73 patients with hepatoblastoma included in 
three studies.17,41,42 In two studies, 5/42 patients relapsed, all 
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detected by rise in alpha-fetoprotein (AFP) levels rather than 
imaging.17,42 One study did not report the number of patients 
relapsed but stated that all were detected by rise in AFP lev-
els prior to imaging.41
In total, 408 imaging studies were performed, although two 
studies only reported CT data without other imaging types. No 
study reported data on overall survival. One study found no 
significant difference in time to relapse between patients de-
tected by surveillance and those detected by symptoms.42
3.3.6 | Neuroblastoma
Five studies described 487 patients with neuroblastoma, 
mostly high-risk disease, of whom 272 relapsed.43–47 Where 
reported, 149 were detected by surveillance imaging and 82 
by symptoms.
Survival statistics were variably reported, with most stud-
ies reporting less than 5-year follow-up. Few patients survived 
following relapse (n = 2 in CR, three alive with disease of 28 
relapses).43,44,46 Curve-estimated 5-year overall survival after 
relapse is around 3% in those detected by surveillance and 0% 
in those detected by symptoms.45
One study reported a mean of 29.5 CT scans per patient 
and another reported a median of 35 images (median CED 
133.5 mSv) from the time of initial diagnosis to relapse.44,47
3.3.7 | Retinoblastoma
Two studies assessed 65 patients with retinoblastoma.48,49 
Three patients relapsed, one was detected by surveillance im-
aging and two by symptoms. A total of 223 scans were con-
ducted and 11 false positive images were reported. Survival 
data are lacking.
3.3.8 | Soft tissue sarcomas
Four studies examined rhabdomyosarcoma and included 466 
patients with 325 relapses.3,50–52 One study included all pedi-
atric soft tissue sarcomas—235 patients with relapsed dis-
ease, of whom 150 had rhabdomyosarcoma.16
In the studies that only included patients with rhabdo-
myosarcoma, where method of detection was reported, 85 
relapses were detected by surveillance imaging and 140 by 
symptoms. In Dantonello et al, 90 were detected by surveil-
lance, and 139 by symptoms. One study reported 507 scans 
in 40 patients, with scanning frequency data not provided by 
other studies.50
Two studies reported survival data.3,51 Neither found a 
significant difference in overall survival between those de-
tected by surveillance and by symptoms. The survival rate 
was lower in one study compared to the other (surveillance vs 
symptoms: 20% vs 11% 3-year survival and 43.3% vs 44.6% 
5-year survival, respectively), as the former included pro-
gression of disease along with relapse. 3,51
In Dantonello et al, 5-year overall survival from primary 
surgery was 40% for those detected by surveillance and 29% 
for those detected by symptoms.16 However, by 10  years, 
survival was 21% for surveillance and 23% for symptomatic. 
These differences may reflect different biology of disease 
being detected by surveillance, with these patients surviving 
longer.
3.3.9 | Other tumors
Eight studies examined 583 patients with unique pediatric 
malignancies, see Table 1 for details.53–60 These studies were 
generally small, all including less than 70 patients, except for 
Geldart et al who included 329 patients. No study reported 
more than 20 relapses. Overall survival was reported in four 
studies.53,56–58 No study reported differences in survival be-
tween groups based on method of relapse detection.
4 |  DISCUSSION
Evidence on the use of surveillance imaging in pediatric ex-
tracranial solid tumors is derived exclusively from observa-
tional studies. Surveillance strategies are often poorly reported 
and variable in design, making replication of many studies 
impossible. The risk of bias for most studies is significant. 
Evidence gaps were present in all malignancies and the qual-
ity of studies was generally low, with particular issues around 
confounding and lead-time bias. Conclusive statements re-
garding the survival benefit of surveillance imaging cannot 
be made based on information identified in this review.
We recognize that reporting combinations of different 
imaging types together makes it challenging to separate out 
the roles of each modality for different malignancies. Sadly, 
much of the available literature includes all imaging types 
and presenting separate findings is currently impossible.
Notwithstanding these limitations, it is possible to estab-
lish that surveillance imaging programs result in large num-
ber of additional imaging investigations, often associated 
with notable radiation doses. There is a risk of false positive 
images, including incidental or uncertain findings, which was 
particularly present in studies of lymphoma. These may be 
associated with additional distress for patients and families, 
as well as further investigations. Even with large numbers 
of tests, surveillance imaging detected only 57% of relapses 
identified.
Survival outcomes were generally poorly reported. For 
most malignancies studied, the data available suggested no 
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significant difference in survival between patients whose re-
lapse was detected by surveillance and those whose relapse 
was detected by symptoms. One exception to this finding is 
within Wilms tumor, where detection by surveillance imag-
ing does appear consistent with increased survival. However, 
the number needed to scan is large and the financial costs of 
surveillance imaging are high. Summary information with 
the clinical bottom line for each cancer type is provided in 
Box 2.
It is important to recognize that any differences in sur-
vival reported in these nonrandomized studies may be due 
to the variable biology of relapsed disease rather than an 
effect of surveillance. As such, randomized studies are nec-
essary in order to truly evaluate the role of routine surveil-
lance imaging in pediatric patients with extracranial solid 
tumors.
No qualitative data, psychological distress indicator 
studies, or studies exploring morbidity or burden of relapse 
treatment, including the risk of secondary malignancies, 
were identified. As such, the literature captures little of 
the patient’s or family’s experience of routine surveillance 
programs, which may be positive, negative, or both, or of 
the subsequent treatment of relapse. This is particularly 
disappointing given our PPI group stressed the importance 
of these issues. They highlighted to us the importance of 
understanding the “sawtooth” of anxiety relating to scan-
ning (“scanxiety”), where the anxiety builds to the point 
of receiving the results of a scan, followed by the relief of 
a result showing no evidence of disease. They discussed 
that there may be different anxieties experienced if routine 
surveillance imaging was not undertaken. They also felt 
the literature should reflect that knowing about a relapse 
Box 2 Clinical bottom lines
Lymphomas
. Large numbers of scans and false positive imaging is demonstrated in the literature. More research is needed on 
whether surveillance imaging provides survival benefit.
Osteosarcoma
Large numbers of scans are conducted. A lack of comparative survival data between relapses detected by surveillance 
vs. symptoms. More research is needed on whether surveillance imaging provides survival benefit.
Ewing’s sarcoma
Surveillance imaging may not detect relapse prior to symptoms. Those detected earlier by symptoms may have more 
aggressive disease and therefore have a lower survival after relapse. Research using appropriate effect measures is 
needed to infer a survival benefit.
Wilm’s tumour
Most relapses were detected by surveillance imaging and this appears consistent with increased survival. Data on 
survival benefit was reported post relapse and at risk of lead-time bias, thus should be interpreted with caution. The 
number needed to scan is large and the financial costs are high.
Hepatoblastoma
Tumour markers detected all relapses in the literature prior to surveillance imaging, though there were few relapses 
reported. Patients received a large number of imaging studies. There is no evidence on the effect of surveillance imag-
ing on survival.
Neuroblastoma
Evidence was derived mostly from high-risk patients. The risk of relapse was high and few patients with relapse 
survived, regardless of the method of detection. Surveillance programmes involved a large number of scans and a 
significant radiation dose.
Retinoblastoma
Large numbers of scans were conducted and were associated with false positive images. There is no evidence on the 
effect of surveillance imaging on the time to detection of relapse or on survival.
Soft tissue sarcoma
Numbers of scans were high and most relapses were detected by symptoms. Evidence does not support improved sur-
vival after relapse of rhabdomyosarcoma in those detected by surveillance imaging. For patients with other soft tissue 
sarcomas evidence is inconclusive.
Other tumours
Minimal data is available on the impact of surveillance in rarer diseases and no evidence suggests improved survival 
with surveillance.
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in advance may not change survival but may alter how life 
was lived, and thus a deeper exploration of the meanings 
surrounding surveillance imaging would be a key contribu-
tion to the literature in the future. We strongly recommend 
that high-quality qualitative research should be performed 
to understand the various roles of follow-up, the meaning 
assigned to surveillance imaging, and the preferences of 
patients, parents, and professionals in this setting. This re-
search should include both those undergoing routine disease 
surveillance and those who are not.
The strengths of this review lie in the robust systematic 
review methodology, informed by extensive PPI engagement 
focused on design, interpretation, and dissemination. One 
key challenge lies in how to address teenage and young adult 
malignancies in systematic reviews. We excluded studies 
where the majority of participants were over 25. For some 
diseases, where the population prevalence straddles this cut-
off (eg, Hodgkin’s lymphoma and germ cell tumors), this 
review does not provide all relevant data. Future reviews of 
these particular malignancies should focus on surveillance 
across the population.
In addition to this, it is important to recognize that there are 
challenges in identifying whether patients are symptomatic at 
the time of surveillance imaging, particularly in retrospective 
studies. Even if this was identified, this was rarely reported 
within the literature. We recognize that some patients may 
have presented with symptoms at the point of surveillance 
and may have therefore been classified either as symptomatic 
or detected by surveillance. The effects of this within the data 
are difficult to predict. It is possible that studies could have 
consistently classified these patients as one mode of detec-
tion over the other. If, for example, patients were more fre-
quently classified as detected by surveillance, it may appear 
that surveillance images identify more relapses than would 
be the case in practice. However, it is unlikely to change the 
duration of survival findings if patients are symptomatic at 
surveillance visits. Future prospective studies should aim to 
capture this information so as to inform our understanding of 
the role of surveillance imaging in this setting.
Concerted effort is required to improve understanding of 
the risks and benefits of surveillance imaging. We strongly 
recommend the review of currently held data from research 
trials or cohorts not currently in the public domain. This may 
include combining data from multiple studies to inform the 
research problem. We also recommend the national and inter-
national trial bodies to consider including the randomization 
of follow-up policies within future trial platforms so as to 
provide further information about best surveillance practices. 
Furthermore, we recognize that surveillance imaging pro-
grams should change over time, as both up-front and relapse 
therapies change, and as the imaging modalities available for 
surveillance develop, resulting in a different balance of risks 
and benefits for patients.
5 |  CONCLUSIONS
At present, there is insufficient evidence to evaluate the 
effects of routine surveillance imaging on survival in most 
pediatric extracranial solid tumors. More high-quality 
focused research is needed that uses appropriate effect 
measures to address the research questions, alongside well-
conducted qualitative data. This should be a key research 
priority considering the substantial impact of imaging on 
patient experience, and the financial and opportunity costs 
to health services.
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